A very common and dangerous disease that affects humans is the chronic kidney disease. It is the type of infections and diseases that affects the kidney causing harmful effects. These diseases if not treated quickly will lead to major complications that can lead to cancer or kidney failure. Many different scientists have worked together trying to find new ways to help treat the disease.
A recent study conducted by a team of researchers from the ERA-EDTA were able to find a new treatment to CKD that might actually be effective enough to treat the disease. The treatment develops a new inhibitor called SGLT2 that works on the aetiology of the CKD. Previous inhibitors used included RAAS blockade which was not as effective as it would be recommended.
This study was led and published by the President of the ERA-EDTA, professor Carmine Zoccali. He commented on the findgins saying, “We are glad that we now have evidence that we can help our patients with this medication. 850 million people worldwide are affected by kidney disease- a worrying figure, and one that continues to rise. In about one third of these patients, around 280 million people, diabetes is the cause of kidney failure. For these patients we now have an effective therapy, the CREDENCE study  provides evidence that SGLT2 inhibitors add to the armamentarium for the treatment of diabetic nephropathy. Many people do not know that patients with chronic kidney disease are at a particularly high risk of many other health outcomes, especially dangerous cardiac complications.”